Hospital Clinic Barcelona
Barcelona, 08036, Spain
NCT Number: NCT04771377
Obesity is considered a chronic disease that increases the risk of developing diseases that reduce life expectancy. The treatment of obesity is complex. However, treatments based exclusively on dietary changes have not shown long-term efficacy especially in people with severe obesity. In contrast, in this group of people bariatric surgery (BS) has shown good long-term results in weight loss and maintenance. These changes are accompanied by significant improvements in health, improved quality of life, and reduced mortality. However, the changes in the digestive system created by BS and the high level of dietary restriction, affect the nutritional status and require a proper supplementation of vitamins and minerals during the follow-up. Intense weight loss during the first few months, coupled with an insufficient amount of protein in the diet, can lead to a loss of muscle mass. Excessive muscle loss during the short-term period can lead to functional repercussions (decreased strength and physical function) and reduced calories that the body burns daily. Naturally, this is especially important in people suffering from sarcopenia before BS, and it occurs more frequently in postmenopausal women. Despite this is known, specific protein intake recommendations after BS have not yet been defined based on scientific evidence. In this context, the first part of our proposal will assess the effect of two levels of protein supplementation: standard (S-PS) versus high (H-PS) on changes in a) body composition, b) energy expenditure, c) metabolic flexibility d) the physical condition during weight loss that follows BS. In addition, in patients with H-PS, the added effect of a physical exercise program, carried out with a personal trainer (professional of sports medicine trainer) virtually, will be evaluated. Protein supplementation and the virtual exercise program will be done during the 4 months following BS, and the results will be studied at 4, 8, and 12 months. Once the results have been defined, it is essential to transfer the recommendations to the real world. In a second part, and to achieve knowledge transfer to clinical practice, the investigators will explore the key elements that influence patient experience (XPA).
Looking for future studies?
Notify Me45 year–75 year
Female
Interventional
Not applicable
Barcelona, 08036, Spain
Obesity is considered a chronic disease that increases the risk of developing diseases that reduce life expectancy. The treatment of obesity is complex. However, treatments based exclusively on dietary changes have not shown long-term efficacy especially in people with severe obesity. In contrast, in this group of people bariatric surgery (BS) has shown good long-term results in weight loss and maintenance. These changes are accompanied by significant improvements in health, improved quality of life, and reduced mortality. However, the changes in the digestive system created by BS and the high level of dietary restriction, affect the nutritional status and require a proper supplementation of vitamins and minerals during the follow-up. Intense weight loss during the first few months, coupled with an insufficient amount of protein in the diet, can lead to a loss of muscle mass. Excessive muscle loss during the short-term period can lead to functional repercussions (decreased strength and physical function) and reduced calories that the body burns daily. Naturally, this is especially important in people suffering from sarcopenia before BS, and it occurs more frequently in postmenopausal women. Despite this is known, specific protein intake recommendations after BS have not yet been defined based on scientific evidence. In this context, the first part of our proposal will assess the effect of two levels of protein supplementation: standard (SP-S) versus high (SP-A) on changes in a) body composition, b) energy expenditure, c) metabolic flexibility d) the physical condition during weight loss that follows BS. In addition, in patients with SP-Alta, the added effect of a physical exercise program, carried out with a personal trainer (professional of sports medicine trainer) virtually, will be evaluated. Protein supplementation and the virtual exercise program will be done during the 4 months following CO, and the results will be studied at 4, 8, and 12 months. Once the results have been defined, it is essential to transfer the recommendations to the real world. In a second part, and to achieve knowledge transfer to clinical practice, the investigators will explore the key elements that influence patient experience (XPA). The investigators will define indicators to assess it, especially those that are related to adherence to nutritional recommendations and to changes in lifestyle. The investigators are currently in the recruitment phase of the study. I have studied the necessary elements, ambitions and included the components that will help to define the dietary and lifestyle recommendations for our population. Aim to facilitate and define the performance of the professionals providing realistic, based on the XPA and in this way to improve the impact of the CO on health and quality of life. This is an ambitious and necessary study and includes all the component that will help define dietary and lifestyle recommendations for our population. It aims to facilitate and define the action of professionals provides realistic tools, based on XPA and thus improve the impact of BS on health and quality of life.
Description of the population to study sedentary women, candidates for BS at our institution.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
women ≥45 years of age who meet CB criteria: Body mass index (BMI) ≥40.0 kg / m2 or between 35.0 and 39.9 kg / m2 with comorbidities (metabolic diseases, cardiorespiratory diseases), sedentary lack of regular physical activity: <30 minutes / day and <3 days / week).
Exclusion criteria
protein supplements will be supplied to participants at no cost physical activity Will be performed virtually by PT
Other names: Physical training, standard protein supplementation
Time frame: 4 months after BS
change from baseline in DEXA values
Time frame: 8 months after BS
change from baseline in DEXA values
Time frame: 12 months after BS
change from baseline in DEXA values
Time frame: 4 months after BS
change from baseline in estimated REE from indirect calorimety
Time frame: 8 months after BS
change from baseline in estimated REE from indirect calorimety
Time frame: 12 months after BS
change from baseline in estimated REE from indirect calorimety
Time frame: 4 months after BS
changes from baseline on prediction of ne repetition máximum (1-RM) and hang grip.
Time frame: 8 months after BS
changes from baseline on prediction of ne repetition máximum (1-RM) and hang grip.
Time frame: 12 months after BS
changes from baseline on prediction of ne repetition máximum (1-RM) and hang grip.
Time frame: 4 months after BS
changes from baseline on sit and stand
Time frame: 8 months after BS
changes from baseline on sit and stand
Time frame: 12 months after BS
changes from baseline on sit and stand
Time frame: 4 months after BS
change in VO2 peak measured by Ergocard during half-effort test
Time frame: 8 months after BS
change in VO2 peak measured by Ergocard
Time frame: 12 months after BS
change in VO2 peak measured by Ergocard during half-effort test
Time frame: 4 months after BS
change in RQ determined by Ergocard during half-effort test
Time frame: 8 months after BS
change in RQ determined by Ergocard during half-effort test
Time frame: 12 months after BS
change in RQ determined by Ergocard during half-effort test
Time frame: 4 months after BS
Time to spend to reach the cross over pony for RQ=1 determined by Ergocard during half-effort test (min)
Time frame: 8 months after BS
Time to spend to reach the cross over pony for RQ=1 determined by Ergocard during half-effort test (min)
Time frame: 12 months after BS
Time to spend to reach the cross over pony for RQ=1 determined by Ergocard during half-effort test (min)
Time frame: 4 months after BS
serum change in BCAA (mcg)
Time frame: 8 months after BS
serum change in BCAA (mcg)
Time frame: 12 months after BS
serum change in BCAA (mcg)
Time frame: 4 months after BS
Nitrogen (mg) values quantified in 24hs urine
Time frame: 8 months after BS
Nitrogen (mg) values quantified in 24hs urine
Time frame: 12 months after BS
Nitrogen (mg) values quantified in 24hs urine
Time frame: 12 months after BS
identify by focus group patient reported outcomes by cualitative study
Time frame: 4 months after BS
weight and height will be combined to report BMI in kg/m^2
Time frame: 8 months after BS
weight and height will be combined to report BMI in kg/m^2
Time frame: 12 months after BS
weight and height will be combined to report BMI in kg/m^2
Time frame: 4 months after BS
fasting glucose (mg) and insulin (miliunits/ liter) will be combined to report Insulin sensitivity in
Time frame: 8 months after BS
fasting glucose (mg) and insulin (miliunits/ liter) will be combined to report Insulin sensitivity in
Time frame: 12 months after BS
fasting glucose (mg) and insulin (miliunits/ liter) will be combined to report Insulin sensitivity in
Hospital Clinic of Barcelona
Other
Effect of Protein Supplementation and a Structured Physical Exercise Program on Changes in Body Composition, Metabolic Flexibility (Energy Consumption of Substrates), and Functionality in Women During Weight Loss Induced by BS
Acronym: SarcoFit
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05631379
Atrophy, Body Composition
Ljubljana, Slovenia
View Trial DetailsNCT03871634
Atrophy, Body Weight
Athens, Kallithea, Greece
View Trial DetailsNCT07710456
Atrophy, Body Weight
View Trial DetailsNCT04272073
Atrophy, Body Weight
Liverpool, United Kingdom
View Trial Details